AdvtBy ,ETHealthWorldJoin the community of 2M+ industry professionals Subscribe to our newsletter to get latest insights & analysis.
Download ETHealthworld App Get Realtime updatesSave your favourite articles Scan to download AppNew Delhi: The diagnosed incident cases of HER2-positive (HER2+) breast cancer in the eight major markets (8MM) are projected to have annual growth rate of 1.5 per cent, ie from 107,352 in 2023 to 123,580 by 2033, stated GlobalData , a medical industry focused data-analysis firm.In its report “HER2-Positive Breast Cancer – Epidemiolog Analysis and Forecast to 2033, the data-analysis firm has estimated the annual toll of cases to grow from 59,598 in 2023 to 68,846 cases by 2033.The report also forecasted that among the 8MM, China is expected to see the highest 52,693 cases, while Spain is expected to have the lowest count at 4,157 cases in the decade.Commenting on the revelations a senior official Bharti Prabhakar, MPH, Associate Project Manager at GlobalData, said, “Increased breast cancer survival contributes greatly to the prevalence of the disease, and there is a large amount of evidence showing that breast cancer mammographic screening is effective in reducing the disease mortality by 25-31 per cent in women invited for screening, and 38-48 per cent in women screened.”“The forecasted growth in the diagnosed incident will be the result of an increase in the elderly population worldwide; a high in disease incidents; increased survival; increased use of HRT in higher-income countries, and increasing survival and incidence in low- and middle-income countries,” Prabhakar added.
Advt
By ,
ETHealthWorld
Join the community of 2M+ industry professionals Subscribe to our newsletter to get latest insights & analysis. Download ETHealthworld App Get Realtime updates
Save your favourite articles Scan to download App
New Delhi: The diagnosed incident cases of HER2-positive (HER2+) breast cancer in the eight major markets (8MM) are projected to have annual growth rate of 1.5 per cent, ie from 107,352 in 2023 to 123,580 by 2033, stated GlobalData , a medical industry focused data-analysis firm.In its report “HER2-Positive Breast Cancer – Epidemiolog Analysis and Forecast to 2033, the data-analysis firm has estimated the annual toll of cases to grow from 59,598 in 2023 to 68,846 cases by 2033.The report also forecasted that among the 8MM, China is expected to see the highest 52,693 cases, while Spain is expected to have the lowest count at 4,157 cases in the decade.Commenting on the revelations a senior official Bharti Prabhakar, MPH, Associate Project Manager at GlobalData, said, “Increased breast cancer survival contributes greatly to the prevalence of the disease, and there is a large amount of evidence showing that breast cancer mammographic screening is effective in reducing the disease mortality by 25-31 per cent in women invited for screening, and 38-48 per cent in women screened.”“The forecasted growth in the diagnosed incident will be the result of an increase in the elderly population worldwide; a high in disease incidents; increased survival; increased use of HRT in higher-income countries, and increasing survival and incidence in low- and middle-income countries,” Prabhakar added.
